To date, vasopressin has been suggested as a second-line vasopressor therapy in patients with septic shock on norepinephrine and persistent arterial hypotension instead of increasing norepinephrine dosage. Nevertheless, the threshold for adding vasopressin remains unclear and vasopressin could increase the risk of ischemia. Therefore, the place of vasopressin in the management of patients with septic shock is still debated with significant heterogeneity between ICUs, as the appropriate timing, dosage and duration of vasopressin therapy remain subjects of clinical debate. The aim of this survey is to get an up-to-date picture of the use of vasopressin in patients with septic shock.
Mathieu JOZWIAK (University Hospital of Nice, France)
Vladimir COUSIN (University Hospital of Geneva, Switzerland)

T